Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
01 2021
Historique:
received: 16 07 2020
revised: 14 08 2020
accepted: 30 08 2020
pubmed: 2 10 2020
medline: 28 4 2021
entrez: 1 10 2020
Statut: ppublish

Résumé

There is only partial overlap in the genetic background of isolated rapid-eye-movement sleep behavior disorder (iRBD) and Parkinson's disease (PD). To examine the role of autosomal dominant and recessive PD or atypical parkinsonism genes in the risk of iRBD. Ten genes, comprising the recessive genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7, and PLA2G6 and the dominant genes LRRK2, GCH1, and VPS35, were fully sequenced in 1039 iRBD patients and 1852 controls of European ancestry, followed by association tests. We found no association between rare heterozygous variants in the tested genes and risk of iRBD. Several homozygous and compound heterozygous carriers were identified, yet there was no overrepresentation in iRBD patients versus controls. Our results do not support a major role for variants in these genes in the risk of iRBD. © 2020 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
There is only partial overlap in the genetic background of isolated rapid-eye-movement sleep behavior disorder (iRBD) and Parkinson's disease (PD).
OBJECTIVE
To examine the role of autosomal dominant and recessive PD or atypical parkinsonism genes in the risk of iRBD.
METHODS
Ten genes, comprising the recessive genes PRKN, DJ-1 (PARK7), PINK1, VPS13C, ATP13A2, FBXO7, and PLA2G6 and the dominant genes LRRK2, GCH1, and VPS35, were fully sequenced in 1039 iRBD patients and 1852 controls of European ancestry, followed by association tests.
RESULTS
We found no association between rare heterozygous variants in the tested genes and risk of iRBD. Several homozygous and compound heterozygous carriers were identified, yet there was no overrepresentation in iRBD patients versus controls.
CONCLUSION
Our results do not support a major role for variants in these genes in the risk of iRBD. © 2020 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 33001463
doi: 10.1002/mds.28318
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

235-240

Subventions

Organisme : Medical Research Council
ID : MR/L023784/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M024962/1
Pays : United Kingdom
Organisme : Parkinson's UK
ID : J-0901
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/N50192X/1
Pays : United Kingdom

Informations de copyright

© 2020 International Parkinson and Movement Disorder Society.

Références

Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration-An update. Nat Rev Neurol 2018;14(1):40.
Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain 2019;142(3):744-759.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet Neurology 2019;18(12):1091-1102.
Gan-Or Z, Alcalay RN, Rouleau GA, Postuma RB. Sleep disorders and Parkinson disease; lessons from genetics. Sleep Med Rev 2018;41:101-112.
Chenbhanich J, Sringean J, Bhidayasiri R. Beyond the classic Segawa disease, GCH1-associated neurodegenerative parkinsonism: practical considerations for physicians. J Mov Disord 2017;10(2):102.
Kilarski LL, Pearson JP, Newsway V, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord 2012;27(12):1522-1529.
Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol 2020;19(2):170-178.
Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci 2012;32(12):4240-4246.
Conedera S, Apaydin H, Li Y, et al. FBXO7 mutations in Parkinson's disease and multiple system atrophy. Neurobiol Aging 2016;40:192.
Guo Y-P, Tang B-S, Guo J-F. PLA2G6-associated neurodegeneration (PLAN): review of clinical phenotypes and genotypes. Front Neurol 2018;9:1100.
Gan-Or Z, Mirelman A, Postuma RB, et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann Clin Transl Neurol 2015;2(9):941-945.
Krohn L, Ruskey JA, Rudakou U, et al. GBA variants in REM sleep behavior disorder: a multicenter study. Neurology 2020;95(8):e1008-e1016.
Gan-Or Z, Amshalom I, Kilarski LL, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015;84(9):880-887.
Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361(17):1651-1661.
Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol 2013;70(6):727-735.
Heckman MG, Soto-Ortolaza AI, Contreras MYS, et al. LRRK2 variation and dementia with Lewy bodies. Parkinson Relat Disord 2016;31:98-103.
Bencheikh BOA, Ruskey JA, Arnulf I, et al. LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. Parkinson Relat Disord 2018;52:98-101.
Dickson DW, Heckman MG, Murray ME, et al. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology 2018;91(12):e1182-e1195.
Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 2017;49(10):1511.
Li J, Ruskey JA, Arnulf I, et al. Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder. Mov Disord 2018;33(6):1016-1020.
Gan-Or Z, Montplaisir JY, Ross JP, et al. The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder. Neurobiol Aging 2017;49:218.
Krohn L, Wu RY, Heilbron K, et al. Fine-mapping of SNCA in rapid eye movement sleep behavior disorder and overt Synucleinopathies. Ann Neurol 2020;87(4):584-598.
Krohn L, Öztürk TN, Vanderperre B, et al. Genetic, structural, and functional evidence link TMEM175 to synucleinopathies. Ann Neurol 2020;87(1):139-153.
O'Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012;338(6114):1619-1622.
Lee S, Emond MJ, Bamshad MJ, et al. Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. Am J Hum Genet 2012;91(2):224-237.
Lücking CB, Dürr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342(21):1560-1567.
Yu E, Rudakou U, Krohn L, et al. Analysis of heterozygous prkn variants and copy-number variations in parkinson's disease. Mov Disord 2020. https://doi.org/10.1002/mds.28299
Reed X, Bandrés-Ciga S, Blauwendraat C, Cookson MR. The role of monogenic genes in idiopathic Parkinson's disease. Neurobiol Dis 2019;124:230-239.
Schneider SA, Alcalay RN. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov Disord 2017;32(11):1504-1523.
Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010;133(4):1128-1142.
Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 2016;86(23):2212-2213.
Fernández-Santiago R, Iranzo A, Gaig C, et al. Absence of LRRK2 mutations in a cohort of patients with idiopathic REM sleep behavior disorder. Neurology 2016;86(11):1072-1073.
Zhang J, Xu C-Y, Liu J. Meta-analysis on the prevalence of REM sleep behavior disorder symptoms in Parkinson's disease. BMC Neurol 2017;17(1):1-6.
Zhang X, Sun X, Wang J, Tang L, Xie A. Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson's disease: a meta and meta-regression analysis. Neurol Sci 2017;38(1):163-170.
Jiang H, Huang J, Shen Y, et al. RBD and neurodegenerative diseases. Mol Neurobiol 2017;54(4):2997-3006.
Lesage S, Condroyer C, Klebe S, et al. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 2012;78(18):1449-1450.
Kumar KR, Weissbach A, Heldmann M, et al. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch Neurol 2012;69(10):1360-1364.

Auteurs

Kheireddin Mufti (K)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.

Uladzislau Rudakou (U)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.

Eric Yu (E)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.

Lynne Krohn (L)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.

Jennifer A Ruskey (JA)

Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.

Farnaz Asayesh (F)

Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.

Sandra B Laurent (SB)

Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.

Dan Spiegelman (D)

Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.

Isabelle Arnulf (I)

Sleep Disorders Unit, Pitié Salpêtrière Hospital, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière and Sorbonne University, Paris, France.

Michele T M Hu (MTM)

Oxford Parkinson's Disease Centre (OPDC), University of Oxford, Oxford, United Kingdom.
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.

Jacques Y Montplaisir (JY)

Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.
Department of Psychiatry, Université de Montréal, Montréal, Québec, Canada.

Jean-François Gagnon (JF)

Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.
Department of Psychology, Université du Québec à Montréal, Montréal, Québec, Canada.

Alex Desautels (A)

Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.
Department of Neurosciences, Université de Montréal, Montréal, Québec, Canada.

Yves Dauvilliers (Y)

National Reference Center for Narcolepsy, Sleep Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France.

Gian Luigi Gigli (GL)

Clinical Neurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy.
Department of Medicine, University of Udine, Udine, Italy.

Mariarosaria Valente (M)

Clinical Neurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy.
Department of Medicine (DAME), University of Udine, Udine, Italy.

Francesco Janes (F)

Clinical Neurology Unit, Department of Neurosciences, University Hospital of Udine, Udine, Italy.

Birgit Högl (B)

Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Ambra Stefani (A)

Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Evi Holzknecht (E)

Sleep Disorders Clinic, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Karel Šonka (K)

Department of Neurology and Centre of Clinical Neuroscience, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

David Kemlink (D)

Department of Neurology and Centre of Clinical Neuroscience, Charles University, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Wolfgang Oertel (W)

Department of Neurology, Philipps University, Marburg, Germany.

Annette Janzen (A)

Department of Neurology, Philipps University, Marburg, Germany.

Giuseppe Plazzi (G)

Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy.

Elena Antelmi (E)

Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Michela Figorilli (M)

Department of Medical Sciences and Public Health, Sleep Disorder Research Center, University of Cagliari, Cagliari, Italy.

Monica Puligheddu (M)

Department of Medical Sciences and Public Health, Sleep Disorder Research Center, University of Cagliari, Cagliari, Italy.

Brit Mollenhauer (B)

Paracelsus-Elena-Klinik, Kassel, Germany.
Department of Neurology, University Medical Centre Göttingen, Göttingen, Germany.

Claudia Trenkwalder (C)

Paracelsus-Elena-Klinik, Kassel, Germany.
Department of Neurology, University Medical Centre Göttingen, Göttingen, Germany.

Friederike Sixel-Döring (F)

Department of Neurology, Philipps University, Marburg, Germany.
Paracelsus-Elena-Klinik, Kassel, Germany.

Valérie Cochen De Cock (V)

Sleep and Neurology Unit, Beau Soleil Clinic, Montpellier, France.
EuroMov, University of Montpellier, Montpellier, France.

Christelle Charley Monaca (CC)

Department of Clinical Neurophysiology and Sleep Center, University Lille North of France, CHU Lille, Lille, France.

Anna Heidbreder (A)

Department of Sleep Medicine and Neuromuscular Disorders, University of Müenster, Müenster, Germany.

Luigi Ferini-Strambi (L)

Department of Neurological Sciences, Università Vita-Salute San Raffaele, Milan, Italy.

Femke Dijkstra (F)

Laboratory for Sleep Disorders, St. Dimpna Regional Hospital, Geel, Belgium.
Department of Neurology, St. Dimpna Regional Hospital, Geel, Belgium.
Department of Neurology, University Hospital Antwerp, Edegem, Belgium.

Mineke Viaene (M)

Laboratory for Sleep Disorders, St. Dimpna Regional Hospital, Geel, Belgium.
Department of Neurology, St. Dimpna Regional Hospital, Geel, Belgium.

Beatriz Abril (B)

Sleep Disorder Unit, Carémeau Hospital, University Hospital of Nîmes, Nîmes, France.

Bradley F Boeve (BF)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Ronald B Postuma (RB)

Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.
Centre d'Études Avancées en Médecine du Sommeil, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada.

Guy A Rouleau (GA)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.

Ziv Gan-Or (Z)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH